* Seeks to apply for approval by March 2010
* Shares down 2.8 percent vs 1.1 pct decline for Nikkei
TOKYO Nov 5 Daiichi Sankyo (4568.T), Japan's
third-largest drugmaker, said on Thursday it has begun a
late-stage trial in Japan for the influenza treatment
laninamivir, a drug that aims to prevent new H1N1 flu as well as
bird flu infections.
Daiichi Sankyo plans to apply for approval of the drug, which
is also known as CS-8958 and which is taken by inhalation, by
March 2010. It aims to bring it to market by March 2011.
Australian drugmaker Biota BTA.AX owns the U.S. and UK
rights to develop and market the drug.
Japan's Shionogi (4507.T) said this week it has applied for
approval of the experimental influenza treatment peramivir, an
intravenous drug, in Japan. [ID:nTFA006488]
It bought the Japan and Taiwan rights to peramivir from U.S.
firm BioCryst (BCRX.O). Peramivir recently gained U.S. approval
approval for emergency use to patients who are severely ill in
Shares of Daiichi Sankyo lost 2.8 percent to 1,746 yen,
underperforming a 1.1 percent decline for the benchmark Nikkei
(Reporting by Yumiko Nishitani; Editing by Edwina Gibbs)